Compounds > neurotensin (1-10)
Page last updated: 2024-12-10

neurotensin (1-10)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3085266
CHEMBL ID408658
MeSH IDM0124203

Synonyms (7)

Synonym
pglu-leu-tyr-glu-asn-lys-pro-arg-arg-pro
l-proline, 1-(n2-(n2-(1-(n2-(n2-(n-(n-(n-(5-oxo-l-prolyl)-l-leucyl)-l-tyrosyl)-l-alpha-glutamyl)-l-asparaginyl)-l-lysyl)-l-prolyl)-l-arginyl)-l-arginyl)-
pyroglutamyl-leucyl-tyrosyl-glutamyl-asparaginyl-lysyl-prolyl-arginy-arginyl-proline
63524-00-5
neurotensin (1-10)
CHEMBL408658
DTXSID30212932
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID196425Relative potency expressed in percent to that of neurotensin was measured using rat stomach strips assay1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.
AID80754Relative potency expressed in percent to that of neurotensin was measured using guinea pig atria1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.
AID196904Relative potency expressed in percent to that of neurotensin was measured using perfused rat heart assay1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis of peptides by the solid-phase method. 6. Neurotensin, fragments, and analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's3 (50.00)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		3.411aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
pyrrolidonecarboxylic acid
Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration.		4.47515-oxoproline;
L-proline derivative;
non-proteinogenic L-alpha-amino acid		algal metabolite
sr141716
[no description available]		3.411amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles		anti-obesity agent;
appetite depressant;
CB1 receptor antagonist
neurotensin (1-8)
neurotensin (1-8) : An 8 amino acid peptide fragment of neurotensin.		2.6730peptide zwitterion;
peptide		human metabolite
mdl 100907
Serotonin 5-HT2 Receptor Antagonists: Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.		3.411
neurotensin
neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91		4.6261peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
neurotensin (1-11)
[no description available]		1.9910
piperidines
Piperidines: A family of hexahydropyridines.		3.411
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9610
Psychoses
[description not available]		03.411
Dementia Praecox
[description not available]		03.411
Psychotic Disorders
Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)		03.411
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		03.411
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9910